The availability of a probiotic is the result of seven years of NIAID-led scientific discovery and research.

Wednesday, June 26, 2024 NIAID Discovery Leads to Novel Probiotic for Eczema Colorized electron micrograph of Roseomonas mucosa bacteria. Image captured by Emily Fitzmeyer and Monica Paneru at Rocky Mountain Laboratories, Hamilton, Montana. Credit: NIAID NIAID scientists discovered that bacteria present on healthy skin called Roseomonas mucosa can safely relieve eczema symptoms in adults and children. That research has led to the availability of a novel over-the-counter topical eczema probiotic. Eczema—also known as atopic dermatitis—is a chronic inflammatory skin condition that affects approximately 20% of children and 10% of adults worldwide.  Learn More National Institute of Allergy and Infectious Diseases  |  National Institutes of Health

---

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. Your subscription may be removed if you do not open our emails for a six-month period. 

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).

                           

---

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107